It was an incredible experience connecting with brilliant minds at the ESMO - European Society for Medical Oncology Congress in Barcelona, Spain. #ESMO24
About us
Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. We are committed to the relentless pursuit of science that can improve the lives of patients. Our unique expertise in medicinal chemistry and biology has enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across Oncology and Inflammation & AutoImmunity. Headquartered in Wilmington, Delaware, Incyte has more than 1,700 employees and operations in North America, Europe and Asia. We are proud to have been recently recognized by Forbes as one of the World’s Most Innovative Companies. Additionally, Incyte has consecutively been named a Top Employer by Science Magazine, placing #2 on the 2020 list. For more information about Incyte, please visit our corporate website at www.incyte.com and follow us on Twitter: www.twitter.com/incyte. See our Community Guidelines: http://bit.ly/2sV0H5W.
- Website
-
http://www.incyte.com
External link for Incyte
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Wilmington, Delaware
- Type
- Public Company
- Specialties
- Oncology, Immuno-oncology, Targeted Therapy, Immunology, and Inflammation
Locations
-
Primary
1801 Augustine Cut-Off
Wilmington, Delaware 19803, US
Employees at Incyte
-
Harry Atkins
Senior Director, Alliance Management, Global Strategy and Corporate Development at Incyte
-
Dana Walters
Medical Regulatory Writer
-
Steven Flostrand
Executive Director, Value, Access & Pricing (Europe) at Incyte
-
Onofrio Mastandrea
Regional Vice President, General Manager | Board Member | Forbes Top 100 Managers 2023
Updates
-
We’re pleased to share that positive data from the Phase 2 AGAVE-201 study in patients with chronic graft-versus-host disease (#GVHD), in partnership with Syndax Pharmaceuticals, was published in NEJM Group. Read more. https://bit.ly/3XLu5aL
-
As part of our continued dedication to those living with blood cancer, #TeamIncyte hosted a blood drive at our Wilmington office. We’re proud to #SolveOn for the blood cancer patient community! #BloodCancerAwarenessMonth
-
+4
-
Squamous cell anal carcinoma (SCAC) is the most common type of anal cancer. Discover more about this condition and explore how we are working to support this patient community. https://bit.ly/4gruTbU
What is SCAC?
-
September 15 marks the beginning of #HispanicHeritageMonth, a time for us to recognize, honor and reflect on the great influence Hispanic Americans have on our society. Hear from our colleagues on what this month means to them.
-
Test your knowledge of the different types of lymphoma and discover how Incyte is dedicated to advancing research in these types of blood cancers. #WorldLymphomaAwarenessDay #SolveOnForBloodCancer #BloodCancerAwarenessMonth https://bit.ly/3B4lyXu
World Lymphoma Day 2024
-
Today, at the ESMO - European Society for Medical Oncology Congress, we shared new data on a CDK2 inhibitor showing evidence of clinical activity in treating certain advanced solid tumors. Learn more. #ESMO2024 https://bit.ly/3XH9vs1
-
Today, at the ESMO - European Society for Medical Oncology Congress, we shared late-breaking research from a Phase 3 study of PD-1 inhibition in squamous cell anal carcinoma (SCAC). Lean more. #ESMO2024 https://bit.ly/3XHGagV
-
We are headed to the ESMO - European Society for Medical Oncology Congress to share the latest data from our #oncology portfolio including late-breaking research featured in the Presidential Symposium. Stay tuned to hear our updates at #ESMO2024. https://bit.ly/47sbZ0P
-
Over the past year, we have made significant progress toward advancing our Global Responsibility initiatives. We are confident the coming year will mark another remarkable chapter in our journey as we continue to advance our commitments to create a healthier future. Read the full 2023 Global Responsibility Report. https://bit.ly/3MKx1y3
Discover our Global Responsibility
Affiliated pages
Similar pages
Browse jobs
Stock
INCY
NASDAQ
20 minutes delay
$66.82
1.65 (2.532%)
- Open
- 66.22
- Low
- 65.27
- High
- 66.95
Data from Refinitiv
See more info on